Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Indivior

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone. ... The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories.

The year of the blockbuster

The year of the blockbuster Emanating from the pipelines of global pharma giants like Novartis, Johnson &Johnson and Pfizer, as well companies such as Denmark’s Novo Nordisk and Indivior and GW Pharmaceuticals, both of the ... Sublocade (buprenorphine) from Indivior:Sublocade,

Deal Watch January 2018

Licence. 350. Addex Therapeutics/ Indivior. ADX71441, selective positive allosteric modulator (PAM) for addiction (pc).

FDA panel backs Indivior’s drug to fight opioid addiction

FDA panel backs Indivior’s drug to fight opioid addiction Indivior is on course to bring a new drug to market to tackle painkiller addiction in the US, offsetting the risks to its business from generic competition. ... An FDA advisory committee backed approval of Indivior’s RBP-6000 drug by a vote of eighteen

Indivior slumps as patent dispute rises US generic spectre

Indivior slumps as patent dispute rises US generic spectre company launches ahead of the appeal outcome it would be at-risk of damages if Indivior's appeal is successful. ... RBP-6000 is due for an FDA verdict by November 30 and according to Indivior could have $1bn or more sales potential.

[ Previous 5 results ] 1 2 3 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics